Monitor for updates on the registrational myositis trial data in mid-2027 and initiation of the SSc-ILD cohort in 4Q26. The cash runway into mid-2027 provides a buffer, but with no near-term catalysts, the stock is likely to trade on pipeline sentiment and broader biotech sector trends.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 13 $2.71entry
- T+1 · 3mo ago +1.48%α +1.67% · $2.75
- T+5 · 3mo ago +17.71%α +19.68% · $3.19
- T+20 · 2mo ago +0.74%α +2.49% · $2.73
- T+60 · 11d ago −52.03%α −46.55% · $1.30
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Cabaletta Bio reported Q2 2026 EPS of -$0.34, beating consensus of -$0.37 by 8.1%, with no revenue. The company highlighted progress in its registrational myositis trial (data mid-2027, BLA 2H27) and plans to initiate a second registrational cohort in SSc-ILD in 4Q26. Cash position strengthened to $225.1M post a $150M May offering, extending runway into mid-2027, but the EPS beat is modest and pipeline milestones remain distant, making this a neutral event.
Key Financial Metrics
Key Facts
- Q2 2026 EPS of -$0.34 beat consensus of -$0.37 by 8.1%
- Cash, cash equivalents, and short-term investments were $225.1M as of June 30, 2026, up from $133.6M at year-end 2025
- Registrational RESET-Myositis data expected mid-2027 with BLA submission in 2H27
- SSc-associated ILD registrational cohort of ~25 patients expected to initiate in 4Q26
- PC-free approach being incorporated into RESET-MG trial
- ElevateBio selected as second CDMO for clinical and commercial manufacturing
Financial Impact
EPS beat of $0.03 (8.1%) vs consensus; cash position increased by $91.5M from year-end 2025 to $225.1M
Risk Factors
- Clinical trial failure or delay in myositis or SSc-ILD programs
- Cash burn rate may require additional financing before mid-2027 if milestones slip
- Competition from other CAR-T therapies in autoimmune diseases
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344398 |
Track record
29 reports on CABA
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +31.59% at T+60 after the May 4, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $1.15 Now $1.11 −3.09% settles Nov 23
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.32 Now $1.11 −15.91% settles Nov 23
- Nov 12, 20264d ago SC 13G/A Neutral 2/10 Entry $1.33 Now $1.11 −16.54% settles Nov 19
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $1.45 Now $1.11 −23.45% settles Nov 17
- Nov 9, 20267d ago 8-K Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 8, 20268d ago Press Release Bullish 6/10 Entry $1.50 to $1.11 Now $1.11 −26.00% ▼ −26.00% −24.31% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $1.30 to $1.28 Now $1.11 −14.62% ▼ −1.54% −4.13% vs SPY
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $1.28 to $1.33 Now $1.11 −13.28% ▲ +3.91% +0.62% vs SPY
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers